Title : Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.

Pub. Date : 2010 Jul-Aug

PMID : 20974575






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Raltegravir has demonstrated good antiviral activity and safety profile in twice-daily (bid) dosing. Raltegravir Potassium BH3 interacting domain death agonist Homo sapiens